covid 19 vaccine implementation
play

COVID-19 vaccine implementation Nancy Messonnier, MD July 29, 2020 - PowerPoint PPT Presentation

ACIP COVID-19 Vaccines Work Group COVID-19 vaccine implementation Nancy Messonnier, MD July 29, 2020 For more information: www.cdc.gov/COVID19 Rising to the challenge to achieve high coverage with COVID-19 vaccines Influenza Vaccination


  1. ACIP COVID-19 Vaccines Work Group COVID-19 vaccine implementation Nancy Messonnier, MD July 29, 2020 For more information: www.cdc.gov/COVID19

  2. Rising to the challenge to achieve high coverage with COVID-19 vaccines Influenza Vaccination Coverage, ≥18 years, by Race/Ethnicity: 2008-09 – 2017-18  Vaccination coverage of racial and 60 ethnic minorities is consistently lower than that of white 50 populations Percent Vaccinated 40 Overall  We need novel and more robust White, NH 30 strategies to increase uptake of Black, NH COVID-19 vaccine, once one 20 Hispanic becomes available Other* 10 0 2008-09 2009-10 2010-11 2011-12 2012-13 2013-14 2014-15 2015-16 2016-17 2017-18 Source: Vaccination Coverage among Adults in the United States, National Health Interview Survey, CDC, 2017. NH = Non-Hispanic. Vaccinations included in this assessment include influenza, pneumococcal, Td, Tdap, Zoster, HepA, HepB, and HPV.

  3. Complex and evolving landscape for COVID-19 vaccine  One vs. two dose series, products not interchangeable  Varying presentations  Vaccine efficacy and adverse event profile in different populations  Varying cold-chain requirements  Use in children and pregnant women  Need for socially distanced vaccination practices  Communication and education  High-risk groups for COVID-19 may distrust public health

  4. Multiple Critical Components to Vaccine Implementation Communication Communication and Stakeholder Guidance and Stakeholder Guidance (state, local, special populations, private sector partners, public) (state, local, special populations, private sector partners, public) Vaccine Vaccine Prioritizing Prioritizing Allocation Allocation Distribution Distribution Safety, Effectiveness, Safety, Effectiveness, Administration Administration Recovery Recovery population population of Vaccine of Vaccine (MFR (MFR –Dist Dist- State) State) Uptake, Second dose Uptake, Second dose Supply Supply - Monitor, Track, Report Monitor, Track, Report Data Vaccine Uptake, Use, and Coverage Vaccine Uptake, Use, and Coverage ADE and VE Monitoring and Reporting ADE and VE Monitoring and Reporting Regulatory Considerations Regulatory Considerations

  5. As volume of doses available increases, we will be able to vaccinate broader populations Ramp up Peak Maximum Volume doses available (per month) Trials only • Constrained supply • Greater supply • Focused administration to target populations • Continued administration to target where high coverage will be essential for populations as well as to general Key public health (e.g., healthcare and essential population factors workers, individuals long-term care and • USG will work to ensure physical & assisted living facility residents) financial access for all

  6. Approach to COVID-19 vaccination Vaccine & ancillary supplies Central distributor Approved Requests Allocation for jurisdictions with additional direct allocations to Requesting select private partners to Vaccine expand access Requesting against allocation Administration sites in traditional & innovative sectors to reach target IT / data infrastructure supports entire distribution, populations ordering, tracking process from end-to-end

  7. To distribute and administer a COVID-19 vaccine, we will leverage many opportunities to ensure success Partnerships with distributor(s) State, local, and community will ensure the vaccine is partners will be instrumental readily and efficiently in planning for widespread distributed across the country vaccination Distributor(s) Partners Diverse administration sites Sites (pharmacies, doctor's offices, IT IT infrastructure will support mobile clinics, etc.) will ensure the entire vaccine ordering, all individuals have physical distribution, and tracking access to the vaccine process from end-to-end

  8. CDC’s strategic framework for strengthening vaccine confidence and preventing outbreaks of vaccine preventable diseases. Strategy: Protect communities at risk from under -vaccination  Protect Leverage immunization data to find and respond to communities at risk  Work with trusted local partners to reach at-risk communities before outbreaks communities  Ensure vaccines are available, affordable, and easy-to-get in every community Strategy: Get providers and parents effective information resources  Expand resources for health care professionals to help them have effective vaccine Empower conversations with parents families  Work with partners to start conversations before the first vaccine appointment  Help providers foster a culture of immunization in their practices Strategy: Stop misinformation from eroding public trust in vaccines  Work with local partners and trusted messengers to improve confidence in vaccines among key, at-risk groups Stop myths  Establish partnerships to contain the spread of misinformation  Educate key new stakeholders (e.g., state policy makers) about vaccines

  9. For more information, contact CDC Thank you 1-800-CDC-INFO (232-4636) TTY: 1-888-232-6348 www.cdc.gov The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Recommend


More recommend